Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Antiangiogenic properties of Koetjapic acid, a natural triterpene isolated from Sandoricum koetjaoe Merr.

Nassar ZD, Aisha AF, Ahamed MB, Ismail Z, Abu-Salah KM, Alrokayan SA, Abdul Majid AM.

Cancer Cell Int. 2011 Apr 27;11(1):12. doi: 10.1186/1475-2867-11-12.

2.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

3.

[Antiangiogenic Effect of Oyster Polypeptide (OPP).].

Wang Z, Liu J, Su A, Sun M, Wang C.

Zhongguo Fei Ai Za Zhi. 2009 Aug 20;12(8):841-8. doi: 10.3779/j.issn.1009-3419.2009.08.02. Chinese.

5.

Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.

Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B.

Cancer Res. 2004 Feb 1;64(3):910-9.

6.

Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1alpha in Ehrlich ascites tumor cells.

Kumar A, D'Souza SS, Nagaraj SR, Gaonkar SL, Salimath BP, Rai KM.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1221-33. doi: 10.1007/s00280-009-0992-y. Epub 2009 Apr 16.

PMID:
19370348
8.

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.

Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R.

Clin Cancer Res. 2004 Jul 15;10(14):4813-21.

9.

Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP.

Pratheeshkumar P, Kuttan G.

Eur J Pharmacol. 2011 Apr 10;656(1-3):10-8. doi: 10.1016/j.ejphar.2010.12.041. Epub 2011 Jan 20.

PMID:
21256125
10.

Plant anticancer agents, L. cytotoxic triterpenes from Sandoricum koetjape stems.

Kaneda N, Pezzuto JM, Kinghorn AD, Farnsworth NR, Santisuk T, Tuchinda P, Udchachon J, Reutrakul V.

J Nat Prod. 1992 May;55(5):654-9.

PMID:
1517737
11.

Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.

He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, Yi Z, Liu M, Pang X.

Cancer Sci. 2011 Jan;102(1):219-25. doi: 10.1111/j.1349-7006.2010.01778.x. Epub 2010 Nov 19.

12.

Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.

Pradeep CR, Sunila ES, Kuttan G.

Integr Cancer Ther. 2005 Dec;4(4):315-21. Review.

PMID:
16282508
13.

Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.

Kong D, Okamura M, Yoshimi H, Yamori T.

Eur J Cancer. 2009 Mar;45(5):857-65. doi: 10.1016/j.ejca.2008.12.007. Epub 2009 Jan 12.

PMID:
19144509
14.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
15.

VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.

Ueda Y, Yamagishi T, Ikeya H, Hirayama N, Itokawa T, Aozuka Y, Samata K, Nakaike S, Tanaka M, Ono M, Saiki I.

Anticancer Res. 2004 Sep-Oct;24(5A):3009-17.

16.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

17.

The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.

Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.

Clin Cancer Res. 2002 Apr;8(4):1242-50.

18.

Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.

Ischenko I, Guba M, Yezhelyev M, Papyan A, Schmid G, Green T, Fennell M, Jauch KW, Bruns CJ.

Angiogenesis. 2007;10(3):167-82. Epub 2007 May 8.

PMID:
17486419
19.
20.

Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR.

Kamiyama H, Kakeya H, Usui T, Nishikawa K, Shoji M, Hayashi Y, Osada H.

Oncol Res. 2008;17(1):11-21.

PMID:
18488711
Items per page

Supplemental Content

Write to the Help Desk